Registered title, quoted from ClinicalTrials.gov
A Study of DS-3939a in Participants With Solid Tumors
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 13 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 13
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
- Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07739966, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC.
Inclusion criterion 3
Participants without AGA: Participants have been previously treated with platinum-based chemotherapy and anti-programmed death-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibody
Inclusion criterion 10
Part 2 only: Participants must have received only 1 or 2 prior lines of anticancer therapy for the advanced disease setting.
Inclusion criterion 11
Prior systemic anticancer therapy targeting MUC1 or TA-MUC1.
Exclusion criterion 1
Prior systemic anticancer therapy with topoisomerase 1 inhibitor or topoisomerase 1 inhibitor-based antibody-drug conjugate (ADCs) (e.g., datopotamab deruxtexan and Sacituzumab govitecan).
Exclusion criterion 2
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 assessed no more than 14 days prior to initiation of trial interventions.
Inclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07739966, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures.
- Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age of consent for trial participation is >18 years old).
- Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC.
- Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days of the first trial intervention.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 assessed no more than 14 days prior to initiation of trial interventions.
- Has adequate organ function.
- Participants must have measurable disease by investigator assessment according to RECIST v1.1.
Additional Inclusion Criteria for Substudy 1:
- Participants must not have received prior systemic therapy for locally advanced unresectable or metastatic NSCLC.
Additional Inclusion Criteria for Substudy 2:
- Participants with AGA (excluding EGFR mutation): Participants have been previously treated with targeted therapy for the AGA and platinum-based chemotherapy for the advanced disease setting.
- Participants without AGA: Participants have been previously treated with platinum-based chemotherapy and anti-programmed death-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibody
- Part 2 only: Participants must have received only 1 or 2 prior lines of anticancer therapy for the advanced disease setting.
Exclusion Criteria:
- Prior systemic anticancer therapy targeting MUC1 or TA-MUC1.
- Prior systemic anticancer therapy with topoisomerase 1 inhibitor or topoisomerase 1 inhibitor-based antibody-drug conjugate (ADCs) (e.g., datopotamab deruxtexan and Sacituzumab govitecan).
- Has spinal cord compression or clinically active central nervous system (CNS) metastases.
- Has multiple primary malignancies.
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
- Has active or uncontrolled human immunodeficiency virus (HIV) infection.
- Has active or uncontrolled hepatitis B virus (HBV)/hepatitis C virus (HCV) infection.
- Any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.
- Current participation in other therapeutic investigational procedures, except for participation in long term survival follow-up (LTSFU) without any investigational treatment.
Quoted from ClinicalTrials.gov, NCT07739966, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07739966, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.